J&J Will Boost OTC Marketing Once Reliable Production Returns
This article was originally published in The Tan Sheet
Johnson & Johnson CEO Alex Gorsky says he expects 75% of OTC products previously recalled to be back on the market in 2013, and the firm will begin prioritizing marketing efforts once a consistent supply of products is restored. The McNeil Fort Washington facility will remain offline another year.
You may also be interested in...
Chattem snaps up Rolaids from Johnson & Johnson subsidiary McNeil, which never restocked the iconic heartburn relief brand after recalling and suspending production in 2010. Sanofi touts Rolaids as “an enduring brand with a deep heritage.”
Valeant picks up skin care OTCs from J&J; FDA finds ‘supplements’ making anti-meningitis claims; Capsugel supplies Mercola.com; investigation charge slows Omega Protein; Vitacost continues diversifying sales mix more news in brief.
FDA shifts its scrutiny of Johnson & Johnson’s OTC drug quality control onto the firm’s consumer devices, including K-Y moisturizers, after finding shortcomings in post-market monitoring and pre-market notification. The agency’s May 22 warning letter does not cite manufacturing issues.